|
Tachykinins
receptor antagonists
Tachykinins receptor antagonists: One therapeutic class for
multiple indications?
The tachykinins were first identified in 1931 however the
therapeutic potential of their receptor antagonists is only
starting to be realized. Tachykinin receptor antagonists have
been strongly implicated for the treatment of at least 6 major
disease groups including CNS disorders, pain, airway disease,
urinary incontinence, emesis and intestinal disfunction. The
often overlapping etiologies of these diseases means that not
only do tachykinin antagonists represent one of the major
pharmaceutical targets of the 21st century but that research
groups already developing this class for one indication must
have a good appreciation of it's full potential. This major
state of the art dossier addresses proof of concept issues
including disease overviews, preclinical data and results from
clinical trials; drug development profiles; markets profiles; a
variety of practical steps designed to optimize in house
development and; strategic analysis of future development needs.
In short this document is designed to be a key reference point
for researchers seeking new targets for a wide variety of
indications or for researchers who are already involved in the
development of tachykinin receptor antagonists but who are
looking to optimize drug development potential:
Dossier statistics: 12,000 words, plus profiles on 8 drugs in
development and on-line access to over 320 citations, 9
PaperSets (these are targeted bibliographies covering entire
areas) and knowledge resources.
Table of contents
+ Abstract
+ Proof of Concept
+ CNS
+ Pain
+ Asthma/COPD
+ Urge Incontinence
+ Emesis/Nausea
+ IBS/Food Allergy
+ Side Effects
+ Drugs in Development
+ Market Size
+ Advantages
+ Experimental Tools
+ Screening Architecture
+ Field Leaders
+ Summary
Publication date: 13th November 2001
About the Author: Dr Jon Goldhill has over 10 years of
academic and industrial research experience including 5 years in
middle management at the French pharmaceutical giants,
Sanofi-Synthelabo. Focussing on a variety of indications
including inflammatory disorders, GI disease, Urological
conditions and cancer, Dr Goldhill was responsible for target
identification and project development. Dr Goldhill is now CEO
and chief analyst at LeadDiscovery and coordinates the
identification of candidate drug discovery projects with
industrial potential.
Price: $499.00 click
here
|
$499.00 on-line format
click
here
|
Projects such as
these are overviewed in full DiscoveryDossiers.
Interested
in the production and circulation of a DiscoveryDossier on your research,
technology or products?
DiscoveryDossiers
~ TherapeuticsAdvances ~ PharmaceuticalSolutions
~ LeadDiscovery ~
Purchase
DiscoveryDossiers
LeadDiscovery and
BioPortfolio aims to provide reliable, insightful analysis on the
biotechnology industry. However, this information is provided "as
is" and no representations or warranties either express or implied
of completeness, accuracy, or of any other nature are made with respect
to this information. This information is neither an offer to sell nor a
solicitation to buy the securities of any company. This information
contains forward-looking statements, which involve risks and
uncertainties which may not be listed. The biotechnology industry is an
emerging industry and the securities of the companies mentioned in this
report have a very high degree of risk and volatility. For this reason,
this information is supplied on the condition that the reader will make
his or her own determination as to its suitability for any purpose prior
to any use of this information. The employees and officers of
LeadDiscovery and BioPortfolio may hold positions in some or all of the
stocks discussed in this report.
This
abstract has been produced by LeadDiscovery Ltd. Founded by life
scientists for life scientists we aim to help industry identify cutting
edge drug discovery options and academic/biotech institutions maximize
the potential of their research. Abstracts strictly reflect the opinion
of LeadDiscovery's editorial panel. While all reasonable efforts are
made to ensure the accuracy of information provided LeadDiscovery and
the publisher BioPortfolio, takes no responsibility for incorrect or
misleading information. LeadDiscovery is designed for educational and
drug development purposes only and is not intended or designed to offer
medical advice or advice of any sort, and must not be used for such
purpose. The information provided through LeadDiscovery and BioPortfolio
should not be used for diagnosing or treating a health problem or a
disease and no reliance should be placed on any information contained in
this abstract or elsewhere on LeadDiscovery's and BioPortfolio's
website. It is not intended to be a substitute for professional care. If
you have or suspect you may have a health problem, you should consult
your physician or other health care provider.
|
|
| |
Nothing in this website should be used in place of personal medical
advice from your own qualified medical practitioner. See
User
Agreement
Send comments and feedback to:
Peter Barfoot
Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472 |
All rights reserved. All other trademarks recognized.
BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK.
No.3312883 VAT No. GB 744 6483 10
Copyright © 1997-2008 - BioPortfolio Limited.
|
|
|
